CA3047221A1 - Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta - Google Patents
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta Download PDFInfo
- Publication number
- CA3047221A1 CA3047221A1 CA3047221A CA3047221A CA3047221A1 CA 3047221 A1 CA3047221 A1 CA 3047221A1 CA 3047221 A CA3047221 A CA 3047221A CA 3047221 A CA3047221 A CA 3047221A CA 3047221 A1 CA3047221 A1 CA 3047221A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sclerostin antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437353P | 2016-12-21 | 2016-12-21 | |
| US62/437,353 | 2016-12-21 | ||
| PCT/GB2017/053850 WO2018115880A1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3047221A1 true CA3047221A1 (en) | 2018-06-28 |
Family
ID=60915566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3047221A Pending CA3047221A1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20200179509A1 (enExample) |
| EP (2) | EP3868780A1 (enExample) |
| JP (3) | JP7050335B2 (enExample) |
| KR (3) | KR20190096409A (enExample) |
| CN (2) | CN117442720A (enExample) |
| AU (1) | AU2017381433B2 (enExample) |
| BR (1) | BR112019012731A2 (enExample) |
| CA (1) | CA3047221A1 (enExample) |
| CL (1) | CL2019001749A1 (enExample) |
| CY (1) | CY1124238T1 (enExample) |
| DK (1) | DK3478719T6 (enExample) |
| ES (1) | ES2862922T7 (enExample) |
| FI (1) | FI3478719T6 (enExample) |
| HR (1) | HRP20210207T4 (enExample) |
| HU (1) | HUE053436T2 (enExample) |
| IL (1) | IL267430B1 (enExample) |
| LT (1) | LT3478719T (enExample) |
| MX (1) | MX2019007161A (enExample) |
| NZ (1) | NZ754676A (enExample) |
| PL (1) | PL3478719T6 (enExample) |
| PT (1) | PT3478719T (enExample) |
| SI (1) | SI3478719T2 (enExample) |
| WO (1) | WO2018115880A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2018115880A1 (en) * | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
| MX2020013899A (es) | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| KR102472582B1 (ko) * | 2020-08-20 | 2022-11-30 | 한림대학교 산학협력단 | 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법 |
| WO2023056355A2 (en) * | 2021-09-30 | 2023-04-06 | Mereo Biopharma 3 Limited | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| EA015166B1 (ru) | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| WO2008061013A2 (en) | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| RS53157B (sr) * | 2007-03-20 | 2014-06-30 | Eli Lilly And Company | Antitela na sklerostin |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| WO2010100200A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
| AU2011239935A1 (en) * | 2010-04-16 | 2012-11-08 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| WO2018115880A1 (en) * | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| JP2020502218A (ja) * | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
-
2017
- 2017-12-21 WO PCT/GB2017/053850 patent/WO2018115880A1/en not_active Ceased
- 2017-12-21 EP EP21152251.1A patent/EP3868780A1/en active Pending
- 2017-12-21 IL IL267430A patent/IL267430B1/en unknown
- 2017-12-21 KR KR1020197021162A patent/KR20190096409A/ko not_active Ceased
- 2017-12-21 CN CN202311429543.0A patent/CN117442720A/zh active Pending
- 2017-12-21 PT PT178231908T patent/PT3478719T/pt unknown
- 2017-12-21 EP EP17823190.8A patent/EP3478719B3/en active Active
- 2017-12-21 KR KR1020247023410A patent/KR20240113615A/ko not_active Ceased
- 2017-12-21 NZ NZ754676A patent/NZ754676A/en unknown
- 2017-12-21 PL PL17823190.8T patent/PL3478719T6/pl unknown
- 2017-12-21 US US16/469,915 patent/US20200179509A1/en not_active Abandoned
- 2017-12-21 HU HUE17823190A patent/HUE053436T2/hu unknown
- 2017-12-21 LT LTEP17823190.8T patent/LT3478719T/lt unknown
- 2017-12-21 DK DK17823190.8T patent/DK3478719T6/da active
- 2017-12-21 FI FIEP17823190.8T patent/FI3478719T6/fi active
- 2017-12-21 BR BR112019012731-3A patent/BR112019012731A2/pt unknown
- 2017-12-21 AU AU2017381433A patent/AU2017381433B2/en active Active
- 2017-12-21 MX MX2019007161A patent/MX2019007161A/es unknown
- 2017-12-21 CA CA3047221A patent/CA3047221A1/en active Pending
- 2017-12-21 SI SI201730627T patent/SI3478719T2/sl unknown
- 2017-12-21 HR HRP20210207TT patent/HRP20210207T4/hr unknown
- 2017-12-21 ES ES17823190T patent/ES2862922T7/es active Active
- 2017-12-21 JP JP2019533586A patent/JP7050335B2/ja active Active
- 2017-12-21 KR KR1020227011791A patent/KR20220051269A/ko not_active Ceased
- 2017-12-21 CN CN201780087087.2A patent/CN110325548B/zh active Active
-
2019
- 2019-06-21 CL CL2019001749A patent/CL2019001749A1/es unknown
-
2020
- 2020-01-02 US US16/733,144 patent/US20200123242A1/en not_active Abandoned
- 2020-12-30 US US17/138,691 patent/US20210253684A1/en not_active Abandoned
-
2021
- 2021-04-02 CY CY20211100286T patent/CY1124238T1/el unknown
- 2021-12-10 JP JP2021200994A patent/JP2022046529A/ja active Pending
-
2023
- 2023-04-07 US US18/297,280 patent/US20230365669A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/669,337 patent/US20240400666A1/en active Pending
- 2024-10-11 JP JP2024179475A patent/JP2025020150A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240400666A1 (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| JP6353500B2 (ja) | Ｄｋｋ１抗体およびその使用方法 | |
| US20250122273A1 (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| US11773171B2 (en) | WNT surrogate molecules and uses thereof | |
| JP6845012B2 (ja) | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 | |
| CN104271122A (zh) | 抗vla1(cd49a)抗体药物组合物 | |
| CN107614532A (zh) | 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 | |
| KR20170045240A (ko) | 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도 | |
| HK40058082A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| HK40007021B (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| HK40007021A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| CA3233220A1 (en) | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221221 |
|
| EEER | Examination request |
Effective date: 20221221 |
|
| EEER | Examination request |
Effective date: 20221221 |